The COVID-19 pandemic has spurred healthcare systems across the world to rapidly redesign their models of care delivery. As such, this pandemic has accelerated the adoption of teledermatology in the United States. However, it remains unknown whether this momentum will be maintained after the pandemic. The future of teledermatology in the United States will be significantly influenced by a complex set of policy, legal, and regulatory frameworks. An understanding of these frameworks will help dermatologists more effectively adopt and implement teledermatology platforms. In this article, we review the current state of teledermatology in the United States, including policy dimensions, the regulatory landscape, market characteristics, and future directions. (JAAD Int 2020;1:202-7.)

Key words: COVID-19; digital health; health policy; teledermatology.

INTRODUCTION

The COVID-19 pandemic has spurred healthcare systems across the world to rapidly redesign their models of care delivery. In order to comply with social distancing efforts, medical practices have accelerated their adoption of telehealth models. Early reports suggest that some practices have increased their proportion of telemedicine visits from 10% before the pandemic to more than 90% during the pandemic.1 Medicare, the largest public payer in the United States, reported that over 9 million beneficiaries received telehealth services from mid-March through mid-June 2020.2 Even before the pandemic, dermatologists in the United States had been at the forefront of implementing telemedicine, with 15% of dermatologists reporting the regular use of telemedicine in 2016.3

In the United States, there are wide geographic disparities in access to expert dermatologic care.4 A nationwide study of the geographic distribution of dermatologists found that there are 4.03 dermatologists per 100,000 residents in metropolitan areas, while there are only 3.06 dermatologists per 100,000 residents in rural areas.5 In addition, the United States has an aging population with an increasing incidence of dermatologic diseases.6,7 Therefore, teledermatology (TD) can potentially improve access to expert dermatologic care.

The earliest descriptions of TD in the United States date back to at least 1972, when dermatologists at Massachusetts General Hospital used a black-and-white television system to remotely diagnose patients at an airport medical station.8 Since then, dramatic advancements in telecommunications, internet connectivity, and information storage have spurred rapid growth in the utilization of TD services. Recent studies have demonstrated that TD services achieve diagnostic accuracy and clinical outcomes comparable to in-person dermatologic consultations.9,10 Furthermore, recent evaluations of TD programs targeted at low income populations showed that TD improved access to dermatologic care without increasing the volume of total dermatologic visits.11-13 This suggests that increased adoption of TD has the potential to increase the efficiency of case triage.

In this article, we review the current state of TD in the United States, including policy dimensions, the
regulatory landscape, market characteristics, and future directions. We describe the TD platforms at the Veterans Health Administration (VHA) and Mayo Clinic to highlight two institutions with long-standing TD programs in the United States.

POLICY DIMENSIONS AND REGULATORY FRAMEWORKS

In the United States, health care facilities are composed of a combination of nonprofit, government-owned, and for-profit organizations. Healthcare coverage is administered through a mixture of private health insurance and public health coverage. Individuals under the age of 65 years are primarily insured through private health insurance provided by employers. However, Americans aged 65 years and older, primarily receive health insurance through Medicare, a public national health insurance program. Medicaid is a public program administered on the state level that provides health insurance coverage to low income individuals. Veterans of the United States military receive healthcare through the federally administered VHA. Table I summarizes these payers and their respective TD coverage.

A 2016 national survey identified 102 active TD programs in the United States, a nearly 3-fold increase from the 37 active programs in 2011. The study found that 62 out of 102 active TD programs were governmental programs associated with the VHA. Of the active, nongovernmental TD programs in the United States, 50% were established in academic institutions, 30% were in private practice, 10% were in medical groups, and the remaining 10% were on virtual office platforms. Virtual office platforms provide direct care to patients and do not require a primary care referral. There are two primary modalities of TD: store-and-forward and live-interactive. Store-and-forward is the most popular TD modality, and accounted for 72% of TD encounters in the United States as of 2018. Store-and-forward is an asynchronous process in which images and health data are transmitted to a clinician for later review. On the other hand, live-interactive is a synchronous process in which the patient and clinician interact in real-time using video conferencing.

Since individual states maintain autonomy over the governance of private payers and Medicaid, there are wide variations in the legal and regulatory frameworks of TD across states. For example, dermatologists face uncertainty surrounding the medical liability and malpractice risk while practicing TD across state lines. In addition, TD can pose risks to patient privacy and security. Dermatologists must ensure that the capture, transmission, and storage of clinical images complies with the federal Health Insurance Portability and Accountability Act statutes along with state specific regulations. The federal government has yet to develop a comprehensive regulatory framework for telemedicine, and this ambiguity may have deterred a wider spread adoption of TD. However, in response to COVID-19, the Department of Health and Human Services issued a decree stating it will not enforce The Health Insurance Portability and Accountability Act statutes on clinicians providing telehealth in good faith during the pandemic. This has fostered clinicians’ comfort in utilizing platforms, such as FaceTime and WhatsApp, to conduct TD visits, even though these platforms are not Health Insurance Portability and Accountability Act-compliant. Additionally, in most states, dermatologists are only allowed to practice TD in the state in which they are licensed. In effect, this limits the ability of dermatologists to practice TD across state lines.

Prior to the COVID-19 outbreak, laws governing reimbursement varied significantly across state lines. All state Medicaid programs provided coverage for live-interactive sessions, yet only 11 states reimbursed store-and-forward services. In terms of private payers, 36 states had passed parity laws requiring private insurers to provide the same coverage for telemedicine services as in-person care. Out of all major payers, Medicare has historically had the most restrictive regulations for the coverage of TD. Prior to 2019, Medicare only covered live-interactive sessions. In 2019, Medicare expanded the coverage to include virtual patient check-ins, as well as store-and-forward services. Medicare virtual patient check-ins allow patients to communicate with their doctors through telephone calls, text messages, email, or patient portals. These check-ins must be initiated by the patient and are only covered if the patient has an established relationship with the provider. Yet these policy changes did not induce broader adoption of TD in the Medicare population due to their relatively low
reimbursement rates. Virtual patient check-ins are reimbursed at approximately $15, and store-and-forward services are reimbursed at approximately $13. For comparison, Medicare reimbursement rates for in-person office visits with established patients range from $22 to $148 based on the level of complexity.

During the COVID-19 pandemic, state Medicaid programs, private payers, and Medicare all issued temporary waivers that provided payment parity between telehealth and in clinic care. However, it remains unclear whether payment parity will be sustained after the pandemic. Table II summarizes the regulatory changes related to the COVID-19 pandemic.

In the United States, payers primarily reimburse dermatologists in a fee-for-service manner. Fee-for-service payment models create incentives that may hinder wider adoption of TD. Currently, dermatologists receive higher reimbursement from procedures than from consultation; thus, dermatologists may prefer in-person visits that result in procedures over TD consultations. Yet, as the United States healthcare system transitions away from fee-for-service toward more integrated, quality based reimbursement models, dermatologists may be incentivized to increase the adoption of TD.

THE VETERANS HEALTH ADMINISTRATION EXPERIENCE

VHA can be broadly described as a veteran specific nationalized health service, more akin to single payer systems, such as the National Health Service in the United Kingdom. The VHA is the nation’s largest integrated system that serves the nation’s more than 18 million veterans. The VHA operates under a congressionally appropriated global budget; therefore, providers are not incentivized by fee-for-service reimbursement. As a unified, government-run system, the VHA has developed one of the nation’s most extensive and prominent TD networks.

Originally designed to improve access for rural veterans, the VHA TD network now includes 62 participating facilities, and it had more than 101,000 store-and-forward TD encounters in 2016. Of these encounters, 71% were completed within 7 days of referral. This is a significantly shorter turnaround time in comparison to the average waiting period of 36 days for a dermatology patient to see a dermatologist in person in the United States. A 2013 randomized controlled trial demonstrated that the VHA store-and-forward TD program achieved equivalent clinical outcomes in comparison to conventional, in-person consultations. In addition, a 2015 study found that, from a societal economic perspective, the VHA TD program was more cost efficient than the conventional referral process. On an institutional level, the VHA has achieved efficiency by developing standardized templates and operational manuals for providers, imagers, and TD readers. In addition, the VHA has developed a rigorous training program for resident physicians to acquire skills in TD imaging.

THE MAYO CLINIC EXPERIENCE

Mayo Clinic is a tertiary care academic medical center with locations in Rochester, Minnesota; Phoenix/Scottsdale, Arizona; and Jacksonville, Florida. Mayo Clinic is one of the pioneering institutions of both telemedicine and TD in the United States. In 1986, Mayo Clinic linked its 3 campuses in Minnesota, Arizona, and Florida by means of a 2-way satellite program to support physicians in remote clinics. In 1996, Mayo Clinic developed a telemicine system that connected its 3 campuses to the King Hussein Medical Center and Amman Surgical Hospital in Amman, Jordan. In 1997, Mayo Clinic established one of the nation’s first store-and-forward TD programs. This initial platform was shown to have an 81% concordance with face-to-face office visits. Since then, Mayo Clinic has expanded its TD presence and recently established a local TD network for uninsured and underinsured populations. Mayo Clinic built a mobile phone-based store-and-forward TD service that integrates data from external community clinics into Mayo Clinic’s electronic health record. In addition, Mayo Clinic implemented a streamlined process that utilized standardized intake templates for TD consultations. By providing standardized, relevant clinical information, Mayo Clinic’s TD program improved management concordance by 117% while reducing face-to-face referrals by 15.1%.

Moreover, the collection of standardized clinical information from TD consultations is part of a broader effort to collect, organize, and aggregate health data. To this end, Mayo Clinic developed a convolutional neural network model to automatically classify and organize dermatology images stored within the institution’s electronic health records. This enables researchers to quickly assemble a cohort of specific image types for

Abbreviations used:
DTC: direct-to-consumer
TD: teledermatology
VHA: Veterans Health Administration
research, rather than manually sifting through individual patient encounters. On an institutional level, Mayo Clinic has prioritized advanced data analytics by developing an enterprise-wide Clinical Data Analytics platform. This platform will utilize Mayo Clinic’s extensive de-identified clinical and molecular data to build novel artificial intelligence and machine learning models. 37

FUTURE DIRECTIONS

Recently, artificial intelligence has made dramatic progress in its applications for image analysis in dermatology. 38-42 The improving performance of artificial intelligence models, therefore, can potentially be applied to improve TD processes. Though existing TD platforms can connect patients and referring physicians to dermatologists across geographic distances, these processes are still relatively time- and labor-intensive for dermatologists. Dermatologists must still spend time manually triaging patients for in-person care. However, a smartphone app can use convolutional neural networks to broadly classify images of skin lesions, and primary care physicians in underserved settings could use such an app to automatically, digitally triage high-risk patients. The benefits of this type of app are 2-fold: 1) patients with serious conditions, such as skin cancers, could receive earlier diagnosis and prevent progression, and 2) patients who do not require dermatologic consultation can receive reassurance and avoid unnecessary treatment and procedures.

In addition, the market reach of direct-to-consumer (DTC) TD platforms has grown rapidly in recent years. DTC TD services often take the forms of websites and mobile applications. These platforms allow patients to obtain dermatologic consultations and prescription medications without any prior physician–patient relationship. The providers must be licensed in the state where the patient lives.

| Table I. Summary of payers and teledermatology coverage in the United States |
| --- |
| **Medicare** | **Medicaid** | **Veterans Health Administration** | **Private insurance** |
| **Patient demographics** | Adults age 65+ years and certain residents with disabilities | Low income adults and children | Members of the military |
| **Government funded** | Federal program | Funded by both federal and state governments | Federal program |
| **% of US population** | 15% | 18% | 3% |
| **Teledermatology coverage** | Primarily live-interactive. Store-and-forward and virtual check-ins also covered but at lower reimbursement rates | Varies by state. All states cover live-interactive. 11 states cover store-and-forward | Primarily store-and-forward with live-interactive as well |
| **Table II. Regulatory changes related to COVID-19** |
| **Payment** | Payment parity between telehealth and in clinic care | Improved the financial viability of telehealth for clinicians and increased adoption of telehealth |
| **Privacy** | Penalties for HIPAA violations that occur in good faith will not be imposed by the Department of Health and Human Services | Allowed clinicians to use platforms that are not HIPAA compliant such as FaceTime and WhatsApp |
| **Licensing** | Some states relaxed or eliminated interstate licensure requirements | Enabled clinicians from out-of-state to practice via telehealth |

HIPAA, Health insurance portability and accountability act.
A 2018 study identified 29 DTC TD services in the United States. Most DTC TD services offer patient consultations within 48 hours. Majority of DTC TD services do not accept health insurance and charge a fee for consultation. The median consultation fee is USD $59. This is comparable to the average office-visit copay of USD $36 paid by patients with private insurance for an in-network consultation. Therefore, these services offer the potential to increase patient convenience and improve access to care. However, these services remain poorly regulated and raise important patient safety concerns. A 2016 study showed that DTC TD services frequently did not provide a patient with the choice of clinician or transparent clinician credentials and proffered diagnoses without adequate medical history-taking. In addition, numerous DTC smartphone apps have recently been developed to detect lesions that are suspicious for melanoma. However, a 2018 Cochrane systematic review noted high rates of false negatives and wide variability in accuracy, with sensitivities ranging from 7% to 73% and specificities ranging from 37% to 94%. As such, none of these apps have achieved United States Food and Drug Administration approval and must demonstrate significant improvements in accuracy before being adopted into clinical practice.

Similarly, legal and regulatory frameworks will have significant implications on the future of TD in the United States. During the COVID-19 pandemic, policymakers incentivized the adoption of TD by providing payment parity. However, moving forward, it remains unclear whether these temporary waivers will be formalized into more permanent statutes. Payment parity incentivizes the increased utilization of TD and has the potential to improve access for underserved patient populations. However, it is not known whether this is financially viable for payers. TD visits are typically shorter than office visits and have lower underlying costs than office visits. Therefore, from the payer’s perspective, payment parity may result in relative overpayment for TD services. Yet, from the physician’s perspective, it will be financially challenging to continue providing TD without payment parity. Taken together, policymakers will have to develop TD reimbursement models that promote access while containing costs.

To the same end, the adoption of TD has been limited by state licensure requirements, which impose significant compliance burdens on physicians practicing across state lines. Policymakers could reduce this burden by providing a federal telehealth practitioner licensing pathway that would enable physicians to more easily practice TD across state lines.

**CONCLUSIONS**

In summary, dermatologists in the United States have a long history of providing care through TD models. The COVID-19 pandemic has accelerated the adoption of TD in the United States; however, it remains unknown whether this momentum will be maintained. In order to maintain this momentum, dermatologists and policymakers should collaborate to develop TD policies and regulations that incentivize improved access, outcomes, and patient experience. The United States healthcare system consists of a broad spectrum of patient populations, payers, reimbursement models, and regulatory frameworks in both the public and private sectors. Therefore, the successes and failures of the United States TD experience can be used internationally to better inform TD policymaking. To the same end, policymakers in the United States would be served well by gleaning insights from international health systems and their TD models.

**REFERENCES**

1. Lonergan PE, Washington SL, Branagan L, et al. Rapid utilization of telehealth in a comprehensive cancer center as a response to COVID-19: cross-sectional analysis. *J Med Internet Res.* 2020;22(7):e19322.
2. Verma S. Early impact of CMS expansion of Medicare telehealth during COVID-19. Available at: https://www.healthaffairs.org/do/10.1377/hblog20200715.454789/full/. Accessed July 27, 2020.
3. Kane CK, Gillis K. The use of telemedicine by physicians: still the exception rather than the rule. *Health Aff (Millwood)*. 2018;37(12):1923-1930.
4. Stitzenberg KB, Thomas NE, Dalton K, et al. Distance to diagnosing provider as a measure of access for patients with melanoma. *Arch Dermatol.* 2007;143(8):991-998.
5. Feng H, Berk-Krauss J, Feng PW, Stein JA. Comparison of dermatologist density between urban and rural counties in the United States. *JAMA Dermatol.* 2018;154(11):1265-1271.
6. Dall TM, Gallo PD, Chakrabarti R, West T, Semilla AP, Storm MV. An aging population and growing disease burden will require a large and specialized health care workforce by 2025. *Health Aff (Millwood).* 2013;32(11):2013-2020.
7. Resneck JS Jr. Dermatology workforce policy then and now: reflections on Dr. Peyton Weary’s 1979 manuscript. *J Am Acad Dermatol.* 2013;68(2):338-339.
8. Murphy RL Jr, Fitzpatrick TB, Haynes HA, Bird KT, Sheridan TB. Accuracy of dermatologic diagnosis by television. *Arch Dermatol.* 1972;105(6):833-835.
9. Peracca SB, Jackson GL, Weinstock MA, Oh DH. Implementation of teledermatology: theory and practice. *Curr Dermatol Rep.* 2019;8(2):35-45.
10. Campagna M, Naka F, Lu J. Teledermatology: an updated overview of clinical applications and reimbursement policies. *Int J Womens Dermatol.* 2017;3(3):176-179.
11. Wang RH, Barbieri JS, Nguyen HP, et al. Clinical effectiveness and cost-effectiveness of teledermatology: where are we now and what are the barriers to adoption? *J Am Acad Dermatol.* 2020;83(1):299-307.
12. Naka F, Lu J, Porto A, Villagra J, Wu ZH, Anderson D. Impact of dermatology eConsults on access to care and skin cancer...
screening in underserved populations: a model for teledermatology services in community health centers. J Am Acad Dermatol. 2018;78(2):293-302.

13. Uscher-Pines L, Malsberger R, Burgette L, Mulcahy A, Mehrrota A. Effect of teledermatology on access to dermatology care among medicaid enrollees. JAMA Dermatol. 2016; 152(8):905-912.

14. De Lew N, Greenberg G, Kinchen K. A layman’s guide to the U.S. health care system. Health Care Financ Rev. Fall 1992;14(1):151-169.

15. Yin KM, Florek AG, Oh DH, McCoy K, Armstrong AW. Teledermatology in the United States: an update in a dynamic era. Telemed J Health. 2018;24(9):691-697.

16. Chuchvara N, Patel R, Srivastava R, Reilly C, Rao BK. The growth of teledermatology: expanding to reach the underserved. J Am Acad Dermatol. 2020;82(4):1025-1033.

17. Tensen E, van der Heijden JP, Jaspers MW, Witkamp L. Two decades of teledermatology: current status and integration in national healthcare systems. Curr Dermatol Rep. 2016;5:96-104.

18. Fogel AL, Kvedar JC. Reported cases of medical malpractice in direct-to-consumer telemedicine. JAMA. 2019;321(13):1309-1310.

19. Hall JL, McGraw D. For telehealth to succeed, privacy and security risks must be identified and addressed. Health Aff (Millwood). 2014;33(2):216-221.

20. Office for Civil Rights. Notification of enforcement discretion for telehealth. Available at: https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-on-enforcement-discretion-telehealth/index.html. Accessed April 12, 2020.

21. State telehealth laws and reimbursement policies. Available at: https://www.chhcpca.org/telehealth-policy/state-telehealth-laws-and-reimbursement-policies-report. Accessed March 8, 2020.

22. PYA. New Medicare payments for virtual services effective January 1, 2019. Available at: https://www.pyapc.com/insight/new-medicare-payments-for-virtual-services-effective-january-1-2019. Accessed March 8, 2020.

23. CMS. Calendar year 2019 Medicare physician fee schedule final rule. Available at: https://www.cms.gov/About-CMS/Story-Pag e/CY-19-FSF-Final-Rule-PPT.pdf. Accessed September 1, 2020.

24. Center for Connected Health Policy. COVID-19 telehealth coverage policies. Available at: https://www.chhcpca.org/resources/covid-19-telehealth-coverage-policies. Accessed June 15, 2020.

25. Rosen AR, Littman-Quinn R, Kovarik CL, Lipoff JB. Landscape of business models in telemedicine. Cutis. 2016;97(4):302-304.

26. Landow SM, Oh DH, Weinstock MA. Teledermatology within the Veterans Health Administration, 2002-2014. Telemed J E Health. 2015;21(10):769-773.

27. Uhlenhake E, Brodell R, Mostow E. The dermatology workforce: a focus on urban versus rural wait times. J Am Acad Dermatol. 2009;61(1):17-22.

28. Whited JD, Warshaw EM, Kapur K, et al. Clinical course outcomes for store and forward teledermatology versus conventional consultation: a randomized trial. J Telemed Telecare. 2013;19(4):197-204.

29. Datta SK, Warshaw EM, Edison KE, et al. Cost and utility analysis of a store-and-forward teledermatology referral system: a randomized clinical trial. JAMA Dermatol. 2015;151(12): 1323-1329.

30. Boyers LN, Schultz A, Baceviciene R, et al. Teledermatology as an educational tool for teaching dermatology to residents and medical students. Telemed J E Health. 2015;21(4):312-314.

31. Whitehead R. The evolution of teledermicine. Teleconference. 1995:9-11. Available at: https://scholar.google.com/scholar?cl uster=10071633808192841259&hl=en&as_sdt=5,24&sciodt=0, 24. Accessed November 1, 2020.

32. Mayo Clinic links with 2 Jordanian facilities. Telemedicine Today. 1996:13. Available at: http://www2.aaos.org/bulletin/ja n96/mayo.htm. Accessed November 1, 2020.

33. High WA, Houston MS, Calabrisi SD, Darge LA, McEvoy MT. Assessment of the accuracy of low-cost store-and-forward teledermatology consultation. J Am Acad Dermatol. 2000;42(S Pt 1):776-783.

34. Costello CM, Cumskey HJL, Maly CJ, et al. Improving access to care through the establishment of a local, teledermatology network. Telemed J E Health. 2020;26(7):935-940.

35. Cumskey HJL, Maly CJ, Costello CM, et al. Impact of standardized templates and skin cancer learning modules for telederermatology consultations. Int J Dermatol. 2019;58(12):1423-1429.

36. Wang MZ, Comfere NI, Murphree DH. Deep learning for automating the organization of institutional dermatology image stores. Annu Int Conf Proc IEEE Eng Med Biol Soc. 2019;2019:4479-4482.

37. Anastasijevic D. Mayo Clinic launches its first Platform initiative. Available at: https://newsnetwork.mayoclinic.org/dis cussion/mayo-clinic-launches-its-first-platform-initiative/. Accessed March 8, 2020.

38. Li C-X, Shen C-B, Xue K, et al. Artificial intelligence in dermatology: past, present, and future. Chin Med J. 2019; 132(17):2017-2020.

39. Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115-118.

40. Haenssle HA, Fink C, Schneiderbauer R, et al. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Ann Oncol. 2018;29(8): 1836-1842.

41. Schlessinger DI, Chior G, Gevaert O, Swetter SM, Ko J, Novoa RA. Artificial intelligence and dermatology: opportunities, challenges, and future directions. Semin Cutan Med Surg. 2019;38(1):E31-E37.

42. Puri P, Comfere N, Darge LA, et al. Deep learning for dermatologists: part II. current applications. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.05.035.

43. Lee KJ, Finnane A, Soyer HP. Recent trends in teledermatology and teledermoscopy. Dermatol Pract Concept. 2018;8(3):214- 223.

44. Fogel AL, Sarin KY. A survey of direct-to-consumer teledermatology services available to US patients: explosive growth, opportunities and controversy. J Telemed Telecare. 2017;23(1):19-25.

45. Henry J Kaiser Family Foundation. 2013 employer health benefits survey. Available at: https://www.kff.org/report-sect ion/2013-summary-of-findings/. Accessed March 8, 2020.

46. Resneck JS Jr, Abrour M, Steuer M, et al. Choice, transparency, coordination, and quality among direct-to-consumer telemedicine websites and apps treating skin disease. JAMA Dermatol. 2016;152(7):768-775.

47. Chucho N, Takwoingi Y, Dinnes J, et al. Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma. Cochrane Database Syst Rev. 2018;12(12):CD013192.

48. Freeman K, Dinnes J, Chucho N, et al. Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies. BMJ. 2020; 368:m127.

49. Shachar C, Engel J, Elwyn G. Implications for telehealth in a postpandemic future: regulatory and privacy issues. JAMA. 2020;323(23):2375-2376.